Abstract

Recently, we identified the homeodomain transcription factor Cut homeobox 1 (CUX1) as mediator of tumour de-differentiation and metastatic behaviour in human insulinoma patients. In insulinomas, CUX1 enhanced tumour progression by stimulating proliferation and angiogenesis in vitro and in vivo. In patients with non-functional pancreatic neuroendocrine tumours (PanNET), however, the impact of CUX1 remains to be elucidated. Here, we analysed CUX1 expression in two large independent cohorts (n = 43 and n = 141 tissues) of non-functional treatment-naïve and pre-treated PanNET patients, as well as in the RIP1Tag2 mouse model of pancreatic neuroendocrine tumours. To further assess the functional role of CUX1, expression profiling of DNA damage-, proliferation- and apoptosis-associated genes was performed in CUX1-overexpressing Bon-1 cells. Validation of differentially regulated genes was performed in Bon-1 and QGP1 cells with knock-down and overexpression strategies. CUX1 expression assessed by a predefined immunoreactivity score (IRS) was significantly associated with shorter progression-free survival (PFS) of pre-treated PanNET patients (23 vs. 8 months; p = 0.005). In treatment-naïve patients, CUX1 was negatively correlated with grading and recurrence-free survival (mRFS of 39 versus 8 months; p = 0.022). In both groups, high CUX1 levels indicated a metastatic phenotype. Functionally, CUX1 upregulated expression of caspases and death associated protein kinase 1 (DAPK1), known as mediators of tumour progression and resistance to cytotoxic drugs. This was also confirmed in both cell lines and human tissues. In the RIP1Tag2 mouse model, CUX1 expression was associated with advanced tumour stage and resistance to apoptosis. In summary, we identified the transcription factor CUX1 as mediator of tumour progression in non-functional PanNET in vitro and in vivo, indicating that the CUX1-dependent signalling network is a promising target for future therapeutic intervention.

Highlights

  • Pancreatic neuroendocrine tumours (PanNET) represent a heterogeneous group of neoplasms with increasing incidence [1]

  • Since no data are available on Cut homeobox 1 (CUX1) expression in non-functional PanNET, we evaluated CUX1 expression in curatively resected non-functional PanNET patients (n = 104) without previous systemic therapy

  • The average staining intensity resulted in a higher CUX1 immunoreactivity score (IRS) in primary tumours, compared to metastases

Read more

Summary

Introduction

Pancreatic neuroendocrine tumours (PanNET) represent a heterogeneous group of neoplasms with increasing incidence [1]. The minority of all pancreatic malignancies are of neuroendocrine origin [2,3]. The majority of PanNET patients are diagnosed with advanced metastatic disease [4,5]. We are able to stratify patients according to clinical, pathological and functional characteristics, the underlying tumour biology and the clinical course are still difficult to predict. Group (ECOG) performance status, metastatic spread, tumour load, chromogranin A (CgA) levels and Ki-67 status [6,7,8,9,10]. Two innovative tools have been developed to improve disease monitoring under systemic therapy: The tumour growth rate (TGR) has advantages over RECIST

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call